Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Breast (Edinburgh, Scotland)·2026
Same author

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.

British journal of biomedical science·2026
Same author

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

Breast (Edinburgh, Scotland)·2026
Same author

Tumor immune microenvironment predicts recurrence after radiotherapy in oropharyngeal squamous cell carcinoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Identification of ribosomal protein eL21 as a novel externalized protein and a target in triple-negative breast cancer.

Cancer gene therapy·2026
Same author

Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

Cancer treatment reviews·2026

Related Experiment Video

Updated: Jun 20, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Emerging technologies for assessing HER2 amplification.

Frédérique Penault-Llorca1, Michael Bilous, Mitch Dowsett

  • 1Départment de Pathologie, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex, France.

American Journal of Clinical Pathology
|September 19, 2009
PubMed
Summary
This summary is machine-generated.

Accurate human epidermal growth factor receptor-2 (HER2) testing is crucial for breast cancer treatment. New bright-field in situ hybridization methods, CISH and SISH, offer reliable HER2 status assessment alongside histologic features.

More Related Videos

Robust Detection of Gene Amplification in Formalin-Fixed Paraffin-Embedded Samples by Fluorescence In Situ Hybridization
03:55

Robust Detection of Gene Amplification in Formalin-Fixed Paraffin-Embedded Samples by Fluorescence In Situ Hybridization

Published on: July 12, 2024

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 20, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Robust Detection of Gene Amplification in Formalin-Fixed Paraffin-Embedded Samples by Fluorescence In Situ Hybridization
03:55

Robust Detection of Gene Amplification in Formalin-Fixed Paraffin-Embedded Samples by Fluorescence In Situ Hybridization

Published on: July 12, 2024

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Area of Science:

  • Oncology
  • Pathology
  • Biotechnology

Background:

  • Human epidermal growth factor receptor-2 (HER2) positivity is a key biomarker for targeted breast cancer therapy with trastuzumab.
  • Accurate HER2 status determination is critical for patient eligibility and treatment selection.
  • Traditional methods include immunohistochemical analysis (IHC) and fluorescence in situ hybridization (FISH).

Purpose of the Study:

  • To review recent advancements in bright-field in situ hybridization techniques for HER2 status assessment.
  • To discuss the application, scoring, and concordance of chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH) in routine diagnostics.
  • To highlight the advantages of bright-field methods over traditional techniques.

Main Methods:

  • Review of recent publications on CISH and SISH techniques for HER2 testing.
  • Comparison of bright-field in situ hybridization methods with immunohistochemical analysis and fluorescence in situ hybridization.
  • Evaluation of results scoring and concordance data for CISH and SISH.

Main Results:

  • Chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH) are newly introduced bright-field in situ hybridization techniques for HER2 status determination.
  • These methods utilize peroxidase enzyme-labeled probes with chromogenic detection, visualized via standard bright-field microscopy.
  • CISH and SISH allow parallel evaluation of histologic features and HER2 status, with stable signals over time.

Conclusions:

  • Bright-field in situ hybridization techniques like CISH and SISH offer a valuable alternative for routine HER2 status assessment in breast cancer diagnostics.
  • These methods combine the benefits of IHC and FISH, enabling simultaneous evaluation of morphology and genetic status.
  • Further research and validation support the integration of CISH and SISH into standard diagnostic workflows for HER2+ breast cancer.